Investigation of the Safety of Intranasal Glulisine in Down Syndrome
Status:
Completed
Trial end date:
2018-10-18
Target enrollment:
Participant gender:
Summary
This study is a single center, randomized, double-blind, placebo-controlled, cross-over pilot
study designed to assess the safety of intranasally (IN) delivered glulisine versus placebo
in patients with DS. Subjects will be randomized into this cross-over study and within
subject comparisons conducted between single treatment of intranasal insulin glulisine and
single treatment of intranasal placebo. All subjects will also receive a single treatment of
placebo prior to randomization to ensure adherence to study procedures.